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Abstract
Purpose The present study was designed to evaluate the
efficacy and safety of a novel, 10% liquid formulation of
intravenous immunoglobulin, stabilized with 250 mmol/L
L-proline (Privigen®), in patients with primary immunode-
ficiency disease.
Materials and Methods Eighty adults and children diag-
nosed with common variable immunodeficiency or X-linked
agammaglobulinemia received intravenous Privigen® in-
fusions (200–888 mg/kg) at 3- or 4-week intervals over a
12-month period, according to their previously established
maintenance dose. The primary endpoint was the annual
rate of acute serious bacterial infections.
Results There were six episodes of acute serious bacterial
infections, corresponding to an annual rate of 0.08; the
annual rate for all infections was 3.55. Mean serum IgG
trough levels were between 8.84 and 10.27 g/L. A total of
1,038 infusions were administered, most of them at the
maximum rate permitted (8.0 mg kg−1 min−1). Temporally
associated adverse events, possibly or probably related to
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study drug, occurred in 9% of infusions, either during or
within 72 h after infusion end.
Conclusion Privigen® is well tolerated and effective for the
treatment of primary immunodeficiency.
Keywords Primary immunodeficiency (PID) .
intravenous immunoglobulin (IVIG) . X-linked
agammaglobulinemia (XLA) . common variable
immunodeficiency (CVID)
Introduction
The discovery over 50 years ago that immunoglobulin
replacement therapy decreased the susceptibility to infection
in patients with IgG deficiencies [1] has led to an ongoing
effort to develop safer and better formulations of human IgG
for the treatment of these patients. Initially, intramuscular
human IgG therapy was the only commonly used treatment
strategy for replacement therapy [2]. Intravenous immuno-
globulin formulations (IVIG) developed in the late 1970s
largely replaced intramuscular therapy and were highly
effective at preventing infections [3–5]. The replacement of
lyophilized IVIG products with ready-to-use liquid formula-
tions has advanced rapidly in the recent years. Liquid IVIG
utilization could save time and effort compared with
lyophilized products, which require reconstitution.
Privigen® is a 10% liquid preparation of polyvalent human
IgG for intravenous administration. Stabilization with L-
proline at pH 4.8 is unique in that it minimizes the formation
of IgG dimers and preserves IgG functional activity without
refrigeration [6–8].
A multicenter, open-label clinical investigation was
conducted to evaluate the safety and efficacy of this novel




Privigen® (also known as IgPro10, CSL Behring AG,
Berne, Switzerland) is a ready-to-use 10% liquid formula-
tion of polyvalent human IgG for intravenous administra-
tion that is stable at room temperature for its entire shelf
life. In vitro studies showed that Privigen is stable at room
temperature up to 36 months, with the content of dimers,
aggregates, and fragments (expressed as percent of permit-
ted specification) being, respectively, 53.7%, 8%, and
38.7% at 18 months, 54.5%, 12%, and 47.3% at 24 months,
and 55.2%, 18%, and 62.3% at 36 months (data not
shown). As with other IVIG preparations, Privigen® is
prepared from large donor plasma pools and therefore
represents the antibody spectrum present in the donor
population [9]. The immunoglobulin Fc and Fab functions
are retained. Analysis of six representative lots showed an
IgG content of 99.2%, with more than 99.8% being
monomers and dimers (typical value for dimers, which are
in equilibrium with monomers, is 6%). IgA is present only
in trace concentrations (8.6±1.8 μg/mL). Privigen® contains
no preservative and has a low sodium content (typically
less than or equal to 1 mmol/L) and osmolality (320±
9 mOsmol/kg) in the physiological range.
Privigen® is stabilized with the naturally occurring am-
phiphilic amino acid L-proline (250 mmol/L=28.8 mg/mL)
at a pH of 4.8. The half-life of L-proline in human plasma is
in the order of 20 min [10]. This formulation was found to
be optimal in preventing IgG denaturation, degradation, or
aggregation. Further, the formulation with L-proline limits
the excessive in situ formation of idiotype/anti-idiotype
dimers, which can precipitate adverse events (AEs),
including inflammatory reactions, upon intravenous infu-
sion [8]. It has been observed that clinical tolerance is
improved by limiting IgG dimer formation [6, 11].
The IgG fraction from plasma is purified by a combina-
tion of cold ethanol fractionation, octanoic acid precipitation,
and anion exchange chromatography. The manufacturing
process includes two dedicated viral clearance steps (pH 4
incubation and nanofiltration) and two partitioning steps
with validated viral clearance characteristics [12, 13].
Study Design
The study was designed as a phase III, open-label, single-
arm investigation to evaluate the efficacy and safety of
replacement therapy with Privigen® in patients with PID.
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Good Clinical Practice
guidelines and the Declaration of Helsinki. Informed consent
was obtained prior to the conduct of any study-related
procedures. All study sites had Institutional Review Board or
Independent Ethics Committee approval as required.
Patients were recruited from study sites in the USA and
Europe. Men and women between 3 and 69 years of age
who had either common variable immunodeficiency
(CVID) or X-linked agammaglobulinemia (XLA), as
defined by the Pan-American Group for Immunodeficiency
and the European Society for Immunodeficiencies [14]
were enrolled. Patients were required to have received
regular IVIG therapy every 3 to 4 weeks for at least
6 months prior to screening and to have had at least one
documented serum IgG trough level of greater than or equal
to 4 g/L during this time. Exclusion criteria included
previous serious adverse reaction to immunoglobulins or
other blood products, selective IgA deficiency or known
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antibodies to IgA, hyperprolinemia, pregnancy, planning a
pregnancy, or breastfeeding.
All patients were to receive a 10% liquid IVIG, Privigen®,
at 3- or 4-week intervals over a 12-month period. Each
patient’s dose and dosing interval were to be consistent with
their prestudy treatment (planned dose of 200–800 mg/kg),
which was to remain unchanged throughout the 12-month
study period unless there was a medically justified need to
change it. Infusions were started at an infusion rate of
0.5 mg kg−1 min−1 and gradually increased to a defined
maximum rate at the investigator’s discretion. A maximum
infusion rate of 4.0 mg kg−1 min−1 was permitted for the first
three infusions and a rate of 8.0 mg kg−1 min−1, for
subsequent infusions.
Routine premedication was not permitted. However, any
patient who experienced an adverse reaction during or soon
after two consecutive infusions was permitted to receive
acetaminophen, antihistamines, nonsteroidal anti-inflamma-
tory drugs, or antiemetics at subsequent infusions at the
discretion of the investigator. The use of corticosteroids as
premedication was not allowed. Other medications taken on
a regular basis were continued.
Efficacy and Safety Assessments
The primary study endpoint was the number of acute
serious bacterial infections [15] (aSBI), including pneumo-
nia, bacteremia/septicemia, osteomyelitis/septic arthritis,
bacterial meningitis, or visceral abscess. All suspected
aSBIs were evaluated by a medical expert in consultation
with the treating physician according to prespecified
essential features for diagnosis set out in the study protocol.
Secondary endpoints included the occurrence of any
infection, number of days missed from work or school
because of illness, number of days hospitalized, days with
use of antibiotics, and personal assessment of overall well-
being (rated on a five-point scale: 1=very well, 2=well, 3=
fair, 4=poor, 5=very poor). Information about infections
was captured through the reporting of AEs and concomitant
medications, respectively. The other secondary endpoints
were evaluated via patients’ diaries, which they had to
update daily. Blood samples for the determination of IgG
trough levels were obtained prior to each infusion.
AEs were defined as any AEs occurring after the start of
treatment, regardless of temporal relationship with the
infusion, and were tracked during and between infusions.
AEs were considered temporally associated with the study
drug infusion if they occurred during infusion or within
72 h after the end of infusion, irrespective of any suspected
relationship to the study drug. AEs were identified during
the infusion by the investigator or study nurse. AE
information between infusions was recorded in patient
diaries and reviewed at each visit.
L-Proline serum concentrations were measured before
and after the first two infusions and prior to the week 12
infusion. Routine chemistry, blood counts, urinalysis, and
direct antiglobulin (Coombs’) test were analyzed at the
same time points as above and additionally at the
completion visit. Postinfusion samples were taken 5 to
20 min after the end of infusions 1 and 2 to evaluate the
immediate effect of Privigen® on laboratory parameters. C-
reactive protein was measured at various time points during
the study. Tests for hepatitis B virus surface antigen
(HBsAg), human immunodeficiency virus (HIV), hepatitis
C virus (HCV), and B19 virus (B19) were performed before
the first infusion and at the completion visit. Vital signs
were assessed at screening, before, during, and shortly after
each infusion, and at study completion.
Statistical Analysis
The primary efficacy endpoint was the annual rate of aSBIs
in the intention-to-treat (ITT) population (all patients who
received Privigen®) and in the per-protocol (PP) population
(all ITT patients who completed the 12-month study period
without major protocol deviations). The objective was to
show that the annual rate of aSBIs per patient was less than
1 [15]. Therefore, the null hypothesis that the annual rate of
aSBIs was greater or equal to 1 was tested by providing the
upper one-sided 97.5% confidence limit of the estimated
rate. It was assumed that the number of aSBIs was Poisson-
distributed [16]. If the upper one-sided 97.5% confidence
limit was less than 1, the null hypothesis was to be rejected.
Secondary efficacy and safety endpoints were analyzed
in the ITT population. A major safety point was the
proportion of infusions with one or more temporally
associated AEs, regardless of causality, the limit for which
was set to an upper one-sided 97.5% confidence interval
(CI) of less than 40% [15].
Results
Patients
The study was performed at 19 sites in the USA (10), France
(3), the UK (2), Germany (2), Belgium (1), and Switzerland
(1). Eighty patients received treatment; 72 patients completed
the study. Of the eight patients who discontinued, four
withdrew consent, three discontinued because of AEs, and
one died. Ten patients were excluded from the PP analyses,
including the eight patients who discontinued treatment and
two patients with other major protocol deviations.
Patient demographics are presented in Table I. More than
half of the patients had been diagnosed at least 5 years prior
to study enrollment.
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Treatment
A total of 1,038 infusions were administered throughout the
12-month study, with 16 of the 80 patients (20.0%)
receiving treatment according to a 3-week schedule and
64 (80.0%) according to a 4-week schedule. The entire
range of individual median doses administered was 200–
888 mg/kg. The majority of patients (50 patients, 62.5%)
received doses between 300 and 500 mg/kg. The mean
doses administered for the 3- or 4-week treatment schedule
were similar (457 vs. 451 mg/kg, respectively). Starting
with the fourth infusion, 86% of the infusions were given at
the maximum permitted rate of 8 mg kg−1 min−1.
Premedication, predominantly diphenhydramine, ibupro-
fen, and paracetamol/acetaminophen, was administered to
8 (10%) of the 80 patients in the ITT population prior to 51
(4.9%) of the 1,038 infusions. Headache, nausea, and chills
were the most frequently cited AEs by patients receiving
premedication. Of the 29 patients who had regularly received
premedication during the 6 months prior to the study, 24
(82.8%) did not require premedicationwhile being treated with
Privigen®. Five patients continued the use of premedication.
Efficacy
During the 12-month study period, there were six episodes of
aSBI: three cases of pneumonia and one case each of septic
arthritis, osteomyelitis, and an iatrogenic visceral abscess
(following bowel perforation as a complication of surgical
procedure; Table II). The annual rate of aSBI was 0.08
(upper one-sided 97.5% CI=0.182) for the ITT population;
similar results were found in the PP population (aSBI annual
rate=0.09; upper one-sided 97.5% CI=0.195). Thus, the
primary endpoint was clearly met.
Sixty-six (82.5%) patients experienced 255 episodes of
any infection (including aSBIs), which resulted in an
annual infection rate of 3.55 per patient. As shown in
Table II, the most common infection was sinusitis. The
majority of infections were classified as mild or moderate in
severity; 16 (6.3%) infections experienced by ten patients
were considered severe. Subgroup analyses did not reveal
differences in infection rates with respect to different age
groups or dose ranges.
Fifty-three (66.3%) patients missed work, school, or
daycare or were unable to perform normal activities due to
illness, resulting in an average annual rate of 7.94 days per
patient. There were five patients who missed greater than or
equal to 30 days each, which contributed substantially to
the overall rate of days missed. Fifteen patients were
hospitalized for a total of 166 days, corresponding to an
annual rate of 2.31 days of hospitalization per patient. Of
166 reported days of hospitalization, 116 were attributed to
two patients with AEs assessed as not related to the study
treatment. The annual rate of antibiotics use was 87.4 days.
The patients’ overall feeling of well-being score was
classified as “well” on the five-point scale, with a mean
of 2.1±0.8 (SD).
Mean serum IgG trough levels ranged from 8.84 to10.27 g/L
(Fig. 1) for all infusions. Individual levels remained stable
over time and were comparable to prestudy levels.
Table II aSBIs and All Other Infections Occurring in Greater Than
5% of Patients
ITT population
No. (%) of patients, N=80
aSBIs 6 (7.5)
Pneumoniaa 3 (3.8)
Septic arthritis 1 (1.3)
Osteomyelitis 1 (1.3)
Visceral abscess 1 (1.3)
All infections 66 (82.5)
Sinusitis 25 (31.3)
Nasopharyngitis 18 (22.5)






Ear infection 6 (7.5)
Urinary tract infection 6 (7.5)
aSBI Acute serious bacterial infection
a Blood cultures were negative in three of the six patients with aSBIs and
were not performed in two patients. In the patient with osteomyelitis,
vancomycin-resistant enterococci and yeast-like fungi were found.
Table I Patient Demographics
ITT population





Mean (SD) 28 (19)
Median (min, max) 25 (3, 69)
Age class, years
3 to <12 19 (23.8)
12 to <16 12 (15.0)
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Safety
The percentage of infusions with temporally associated AEs
at least possibly related to therapy was 9%. The percentage
of infusions with at least one temporally associated AE was
21%, and thus the main safety endpoint was met. Headache
(35 patients, 43.8%), fatigue (13 patients, 16.3%), and
nausea (ten patients, 12.5%) were the most frequently
reported temporally associated AEs by patients during the
12 months of this study (Table III). The proportion of
patients with temporally associated AEs was highest after
the first infusion (31 of 80 patients, 38.8%), decreased with
subsequent infusions, and stabilized at approximately 18%
from infusion 5 on (Fig. 2). There was no dose-dependent
increase in the proportion of patients with temporally
associated AEs. Twenty of 25 (80.0%) patients receiving a
median dose between 200 and less than or equal to 400 mg/
kg, 36 of 44 (81.8%) patients receiving 400 to less than or
equal to 600 mg/kg, and 8 of 11 (72.7%) patients receiving
greater than or equal to 600 mg/kg experienced a
temporally associated AE. The figures for the proportion
of infusions with temporally associated AEs in the
respective dose groups were 19.4%, 21.8%, and 19.9%.
Seventy-eight (97.5%) patients reported at least one AE
during the 1-year study period. Headache was the most
frequently reported AE, with 67.5% of patients experienc-
ing 230 events of headache during the 26,198 study days
(rate per infusion=0.22). The majority of the 1,330 AEs
were mild (60%) and not related to study treatment (84%).
Nineteen temporally associated AEs occurred during 684
infusions carried out at an infusion rate of 8 mg kg−1 min−1
(2.8% per infusion). This incidence of AEs was similar to
the incidence seen in the lowest infusion rate category of
less than 4 mg kg−1 min−1: 21 temporally associated AEs
in 1,038 infusions or 2.0% per infusion. AEs starting
during the infusion were observed in 11.8% of infusions.
On just 21 occasions, the infusion rate was adjusted in
response to AEs. This represents 2% of all infusions
affecting 12 (15%) patients.
During the study, 16 (20%) patients experienced 38
serious AEs. Only in one patient, serious AEs were related































Fig. 2 Proportion of infusions with temporally associated AEs (72 h),
by infusion. The proportion of patients reporting temporally associated
adverse events within 72 h of the infusion decreased with subsequent
infusions. Data from both the 3- and 4-week treatment schedules were
pooled for this graph, with the number of available observations
ranging from 80 (at infusion 1) to 71 (at infusion 13). Infusion 13 was
the last infusion for patients on a 4-week schedule; patients on a 3-
week schedule received an additional four infusions (infusions 14–17,
data not shown)
Table III Most Frequent (>5%) Temporally Associated Adverse
Events (within 72 h)
Preferred term Safety population












Stomach discomfort 5 (6.3)















Fig. 1 Mean (±SD) serum IgG trough levels. Time 0 weeks indicates
baseline (before the first Privigen® infusion). Mean trough serum IgG
levels were approximately 9 to 10 g/L, remaining relatively constant
throughout the study. The difference in IgG concentrations between
the two schedules was not statistically significant (p=0.7114)
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hypersensitivity reaction during the second infusion for
which five serious AEs were reported (hypersensitivity,
chills, fatigue, dizziness, and body temperature increased).
The patient was withdrawn from the study. One patient
was diagnosed with lymphoproliferative disorder approx-
imately 6 months into the study and subsequently died of
associated multisystem organ failure. Based on the
patient’s history, the investigator determined that death
was not related to the study treatment.
Laboratory Parameters
Analysis of laboratory variables also revealed no clinically
relevant findings. The direct Coombs’ test changed from
negative at baseline to positive in blood samples taken
immediately after the first or second infusion in 33 (42.9%)
of 77 patients, primarily in patients with blood group A or
B. After infusion 1, 24 patients had a positive Coombs’ test;
21 of them were negative prior to infusion 2. There was no
relationship between positive Coombs’ tests and the
frequency of temporally associated AEs: 25 (75.0%) of
the 33 patients with positive Coombs’ result after infusion 1
or 2 experienced temporally associated AEs compared to 36
(81.9%) of 44 patients whose Coombs’ test had been
negative. No hemolytic events were detected in association
with a positive Coombs’ test. One patient with a number of
confounding medical conditions (osteomyelitis, leg ampu-
tation) experienced a clinically significant increase in C-
reactive protein (48 mg/L). Thirty-eight additional patients
experienced minor, transitory C-reactive protein elevation,
although none exceeded the upper limit of the normal range
(10 mg/L). No positive viral markers (HIV, HCV, B19, or
HBsAg) were found at any of the time points tested. The
mean L-proline serum concentration prior to infusion 1 was
245 μmol/L. Subsequent preinfusion concentrations had
returned to this baseline level. Postinfusion serum levels of
L-proline transiently increased to a range from 496 to
3,997 μmol/L (median=1,927 μmol/L after infusion 1,
1,793 μmol/L after infusion 2).
Discussion
This study demonstrated the efficacy and safety of a novel,
proline-stabilized 10% liquid IVIG preparation in patients
with CVID and XLA. A survey by the Immune Deficiency
Foundation indicated that patients with CVID and agam-
maglobulinemia together represent approximately 77% of
PID patients currently receiving IVIG replacement therapy
in the USA and that the 3- or 4-week dose schedule is used
in 81% of patients [17]. The doses of Privigen® adminis-
tered in this study were representative of those used in
clinical practice.
An annual aSBI rate below 1 is recognized by the US
Food and Drug Administration as indicative of efficacy for
IgG substitution [18]. The study met its primary efficacy
endpoint with an annual aSBI rate of 0.08. This rate is
comparable to the rates recently observed with other IVIG
preparations in patients with PID [19–21]. Furthermore, the
annual rate of any infection (3.55, including aSBI) reported
in this study is consistent with annual infection rates in
other published reports [20–22].
The annual rate of days missed from school or work
reported herein was 7.94 days, comparable with other
studies finding 4.8–6.2 days missed per year [19, 21, 22].
This is in line with statistics reported by the Work Loss
Data Institute, which shows that, on average, the typical
(nonimmunocompromised) US worker had missed 8.5 days
of work in the year 2000 [23]. The annual rate of 2.31 days,
for patients in the ITT population, is higher than the mean
number of days hospitalized per patient year reported in
two recently published studies [19, 21]. This is most likely
due to a disproportionate amount of time spent in the
hospital by just two patients in this study.
The minimum serum concentration of IgG necessary for
protection has not been established in randomized and
controlled clinical studies. However, based on clinical
experience, a target serum IgG trough level of at least
5 g/L has been proposed in the literature for IVIG therapy,
with even further protection achieved at levels of 9 g/L and
higher [24–27]. Mean serum IgG trough concentrations
remained between 8.84 and 10.27 g/L over the course of
this study, comparable to trough levels reported in other
recent studies [19–22].
Privigen® was safe and well tolerated, with the majority
of AEs assessed as mild. Headache has been the most
common AE observed for other IVIG products [7, 14, 21,
22]. This was also the case in the present study. The
proportion of infusions with reports of temporally associ-
ated AEs (21%) in this study compares favorably with data
obtained with two other recently studied liquid IVIG
preparations: 24.9% [28] and 29.1% [29]. The proportion
of infusions with temporally associated AEs declined with
infusion number, consistent with previous observations that
first-time use of IVIG or change in IVIG preparation is
associated with a higher incidence of AEs [30]. Further-
more, as the later infusions were carried out at high infusion
rates, the decline in AE rate is particularly impressive.
Tolerability of IVIG products has been shown to correlate
positively with the infusion rate. In the current study, the
maximum infusion rate stipulated (8 mg kg−1 min−1)
was higher or in the same range than the infusion rate in
studies of other IVIG products [19–22]. Most patients
received infusions at the maximum allowable infusion rate
in our study, and yet infusions were very rarely stopped or
interrupted because of AEs. Decreases in infusion rate
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were required only in 2% of infusions, indicating good
tolerability of Privigen® even at relatively high infusion
rates.
Due to its short half-life, the serum concentrations of the
amino acid stabilizer L-proline returned to baseline levels
prior to subsequent infusions, indicating that proline does not
accumulate during treatment with Privigen®. The highest
Privigen® dose administered in this study, 888 mg/kg, equals
244 mg/kg of L-proline. For comparison, the daily dose of
L-proline administered repeatedly for intravenous nutrition
in newborn infants amounts to 245 mg/kg L-proline.
Positive Coombs’ results were seen shortly after Privigen®
infusions 1 and 2. Most of the patients with positive Coombs’
test after infusion 1 were negative before infusion 2. Tran-
siently positive Coombs’ results may be due to the presence of
anti-A and anti-B antibodies in Privigen® coating B and A
red blood cells and leading to their rapid clearance between
two infusions. Direct Coombs’ test changes from negative at
baseline to positive were observed in 46.8% of patients, which
is comparable to the rate of 37% reported for another IVIG
product [22]. Transiently positive Coombs’ tests are a well-
known phenomenon of IVIG treatment in general [31]. The
timing of blood sampling and the analyses performed were
not designed to detect and fully evaluate laboratory signs of
hemolysis; no clinical signs of hemolytic anemia were
observed in this study.
Conclusions
The present study met both the efficacy and the safety
endpoints. It demonstrates stable IgG trough serum levels, a
very low annual aSBI rate, and a low proportion of infusions
with temporally associated AEs, which attest to the efficacy
and safety of Privigen® treatment in patients requiring
regular immunoglobulin replacement therapy. The combina-
tion of well-tolerated high infusion rates and convenience of
use due to room temperature storage would be potentially
advantageous for both patients and healthcare personnel.
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